Surface Oncology, Inc. (SURF)
| Market Cap | 484.05M |
| Revenue (ttm) | 39.03M |
| Net Income (ttm) | -23.97M |
| Shares Out | 40.00M |
| EPS (ttm) | -0.74 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 27 |
| Last Price | $11.02 |
| Previous Close | $11.90 |
| Change ($) | -0.88 |
| Change (%) | -7.39% |
| Day's Open | 11.31 |
| Day's Range | 10.70 - 11.65 |
| Day's Volume | 988,062 |
| 52-Week Range | 1.44 - 13.82 |
Investors need to pay close attention to Surface Oncology (SURF) stock based on the movements in the options market lately.
CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor m...
Surface Oncology, Inc. (SURF) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
GSK will have exclusive rights to develop and commercialize SRF813, a novel antibody targeting PVRIG
Biotech investors had more than just vaccines to think about this year.
CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor m...
These three stocks are loaded with potential, but need to be watched carefully over the next few weeks.
Both programs have successfully escalated to dose levels demonstrating pharmacodynamic activity without dose - limiting toxicities
CAMBRIDGE, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor m...
CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor m...
CAMBRIDGE, Mass, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor mi...
SRF388 inhibit s hepatocellular carcinoma tumor growth as a single agent in a preclinical model
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Crystal structure of IL-27 in complex with SRF388 demonstrates inhibition of downstream signaling events and provides basis to measure therapeutic inhibition of IL-27 Crystal structure of IL-2...
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
The small biotech could be preparing to sell to a big drugmaker.
The small-cap stocks have outperformed their large-cap peers in the market's turnaround from the September turmoil.
CAMBRIDGE, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumo...
As of late, it has definitely been a great time to be an investor Surface Oncology.
CAMBRIDGE, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumo...
CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Surface Oncology (SURF) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
CAMBRIDGE, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tum...
CAMBRIDGE, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
With the S&P 500 looking to hold on to positive year-to-date gains despite a recession, you may be wondering how long this rally can last.
Shares of micro-cap biopharma Surface Oncology Inc (NASDAQ: SURF) are advancing strongly Wednesday following an oncology partnership the company announced with Merck & Co.
CAMBRIDGE, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumo...
CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumo...
Surface Oncology Inc (SURF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., April 23, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tu...
Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Candidate SRF617
CAMBRIDGE, Mass., March 17, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tu...
Is (SURF) Outperforming Other Medical Stocks This Year?
Is (SURF) Outperforming Other Medical Stocks This Year?
As of late, it has definitely been a great time to be an investor Surface Oncology, Inc. (SURF).
Company focuses efforts and resources on advancing SRF617 and SRF388; Implements strategic restructuring
CAMBRIDGE, Mass., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumo...
Details clinical plans for phase 1/1b clinical studies of SRF617 and SRF388 in patients with advanced solid tumors
Surface Oncology, Inc. (SURF) delivered earnings and revenue surprises of -5.17% and -86.24%, respectively, for the quarter ended September 2019.
Company to provide additional updates at its inaugural R&D day on November 18th in New York Company to provide additional updates at its inaugural R&D day on November 18th in New York
CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumo...
Chief medical officer at Parker Institute for Cancer Immunotherapy to add immuno-oncology clinical development & industry leadership experience Chief medical officer at Parker Institute for Ca...
Surface Oncology, Inc. (SURF) delivered earnings and revenue surprises of -3.23% and -94.28%, respectively, for the quarter ended June 2019.
Surface Oncology, Inc. (SURF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Surface Oncology, Inc. (SURF) delivered earnings and revenue surprises of 65.91% and 477.36%, respectively, for the quarter ended March 2019.
About SURF
Surface Oncology, a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; SRF388 targeting interleukin 27; and SRF813 targeting CD112R. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells and natural killer cells. The company has a strategic collaboration agreeme... [Read more...]
| Industry Biotechnology | IPO Date Apr 19, 2018 |
| CEO J. Jeffrey Goater | Employees 49 |
| Stock Exchange NASDAQ | Ticker Symbol SURF |
Financial Performance
In 2019, SURF's revenue was $15.36 million, a decrease of -74.15% compared to the previous year's $59.42 million. Losses were -$54.79 million, 730.5% more than in 2018.
Analyst Forecasts
According to 5 analysts, the average rating for SURF stock is "Strong Buy." The 12-month stock price forecast is 15.40, which is an increase of 39.75% from the latest price.